Certain HTN Meds May Cut Deaths From Influenza, Pneumonia
Use of ACE-I/ARB vs nonuse linked to lower mortality for those hospitalized with flu, pneumonia.
Cardiovascular Disease
Neurologic Complications Seen in Hospitalized COVID-19 Patients
Neurologic disorders tied to increased risk for in-hospital mortality.
Higher Levothyroxine Doses Linked to Afib in Older Patients
To evaluate the association, the study authors utilized healthcare databases from Ontario, Canada to identify adults 66 years of age and older with no history of AF who filled at least 1 prescription for levothyroxine.
Ertugliflozin Noninferior for CV Outcomes in T2DM With ASCVD
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events.
FDA Approves New Formulation of Ultomiris for PNH and aHUS
The FDA has approved a new 100mg/mL formulation of Ultomiris® (ravulizumab-cwvz; Alexion Pharmaceuticals) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and for atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and pediatric patients.
Mixed Results for Omecamtiv Mecarbil in Heart Failure Study
Findings showed the study met the primary end point of reduction in cardiovascular death or heart failure events.
Hydroxychloroquine Not Beneficial for SARS-CoV-2 Preexposure Prophylaxis
No clinical benefit seen versus placebo for hospital-based health care workers exposed to patients with COVID-19.
Review: Estimated Prevalence of VTE 14.1% in COVID-19
Venous thromboembolism found in 7.9% of non-ICU patients, 22.7% of ICU patients
Dapagliflozin Gets Breakthrough Therapy Status for CKD Indication
The designation was granted based on results from the phase 3 DAPA-CKD trial, which was stopped early due to “overwhelming efficacy”.
Major Adverse CV Event Risk Reduced With SGLT2 Inhibitors
Risks for MACE, MI, cardiovascular death, heart failure, all-cause mortality lower versus DPP-4 inhibitors
